文献速递胃肠动力与功能性疾病

随机临床试验:痛泻要方颗粒对比安慰剂治疗腹泻型肠易激综合征患者

Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2018-06-01

这项双盲、安慰剂对照随机试验纳入160例腹泻型肠易激综合征(IBS-D)患者,随机接受痛泻要方(TXYF)颗粒或安慰剂治疗4周并随访8周。TXYF组在治疗第1-4周达到IBS-D整体症状充分缓解的比例显著高于安慰剂组(57.5% vs 37.5%,P=0.017),大多数次要结局在第3-7周周评估中显示TXYF优于安慰剂,两组不良事件率均较低(3.8% vs 3.8%,P=1.000)。

要点

  • TXYF组第1-4周整体症状充分缓解率57.5%,安慰剂组37.5%(P=0.017)。
  • Logistic回归显示TXYF与充分缓解相关(OR 2.2,95%CI 1.2-4.4,P=0.016)。
  • 两组不良事件率均为3.8%(P=1.000),未见安全性差异。

核心结论

  • 在为期4周的试验中,痛泻要方颗粒在控制IBS-D症状方面优于安慰剂。

研究设计与样本

  • 双盲、安慰剂对照随机试验,纳入160例IBS-D患者,治疗4周并随访8周。
  • 入组条件为IBS-D整体症状VAS评分≥3 cm,且每周≥2天腹痛伴稀便(Bristol评分5、6或7分)。
  • 155/160例患者完成试验。

主要发现

  • 第1-4周整体症状充分缓解率TXYF组57.5% vs 安慰剂组37.5%(χ2=5.6391,P=0.017)。
  • Logistic回归分析显示相似结果(OR 2.2,95%CI 1.2-4.4,P=0.016)。
  • 大多数次要结局在第3周至第7周的周评估中显示TXYF优于安慰剂。
  • 不良事件率两组均为3.8%(P=1.000)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tong-Xie-Yao-Fang (TXYF) is a Chinese herbal formula for treating chronic diarrhoea accompanied by abdominal pain. The results were inconsistent in previous trials examining its effect. AIM: To study the efficacy of TXYF granules for treating diarrhoea-predominant irritable bowel syndrome (IBS-D). METHODS: We performed a double-blind, placebo-controlled randomised trial and enrolled 160 participants with IBS-D. The participants had VAS scores ≥3 cm in IBS-D global symptoms and ≥2 days in a week with abdominal pain and loose stools (Bristol score 5, 6 or 7). They were randomly assigned to received TXYF or placebo during a treatment period of 4 weeks, and they were followed up for 8 weeks after treatment. The primary outcome was adequate relief of IBS-D global symptoms for at least 2 of 4 weeks during weeks 1-4. Secondary outcomes included mean weekly VAS scores of IBS-D major symptoms, mean weekly stool frequency, mean weekly Bristol score, and adverse events. RESULTS: 155 of 160 patients completed the trial. We found a significantly higher rate of adequate relief of global symptoms in TXFY group during weeks 1 to 4 (57.5% vs 37.5%, χ2 = 5.6391, P = 0.017); logistic regression analysis showed a similar result (OR 2.2, 95% CI 1.2-4.4, P = 0.016). Most of the secondary outcomes showed superiority of TXYF over placebo in weekly assessment from week 3 to week 7. The adverse event rate was low in both groups (3.8% vs 3.8%, P = 1.000). CONCLUSION: During a 4 week trial, TXFY granules were superior to placebo in controlling symptoms of IBS-D.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chen M, Tang TC, Wang Y, et al. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018. PMID: 29856472. doi:10.1111/apt.14817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。